Michael Lahn

4PUBLICATIONS
37CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Infectious agentsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Sep 22, 2023
Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma.

Silvia Pietrobono, Fabio Sabbadini, Monica Bertolini

|Sep 05, 2023
Non-Clinical Toxicology Evaluation of the Novel Non-ATP Competitive Oral PI3 Kinase Delta Inhibitor Roginolisib.

Lars van der Veen, Michael Schmitt, Marcel A Deken

|Apr 17, 2023
IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.

Zoë Johnson, Chiara Tarantelli, Elisa Civanelli

|Apr 08, 2020
A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia.

Jason D Lickliter, Hui K Gan, Mark Voskoboynik

Pageof 1

Frequent Collaborators

2 joint publications

Giusy Di Conza

2 joint publications

Lars van der Veen

1 joint publications

Mark Voskoboynik

1 joint publications

Howard Kallender